Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
Clinical Microbiology and Infection（2022）
摘要
SpikoGen® had an acceptable safety profile and induced promising humoral and cellular immune responses against SARS-CoV-2.
更多查看译文
关键词
SpikoGen,Phase 2,Subunit protein vaccine,SARS-CoV-2,COVID-19,Advax-CpG
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要